BlackRock Discloses 5.0% Stake in Mirum Pharmaceuticals
Ticker: MIRM · Form: SC 13G · Filed: Jan 31, 2024 · CIK: 1759425
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, beneficial-ownership, passive-investing
TL;DR
**BlackRock owns 5% of Mirum Pharma, a bullish signal from a major player.**
AI Summary
BlackRock Inc., a massive investment firm, reported on January 31, 2024, that it holds a significant stake in Mirum Pharmaceuticals, Inc. As of December 31, 2023, BlackRock owns 5.0% of Mirum's Common Stock. This matters to Mirum shareholders because BlackRock is a major institutional investor, and its continued holding signals confidence in the company's long-term prospects, potentially attracting other investors.
Why It Matters
This filing shows that a major institutional investor, BlackRock, has a substantial stake in Mirum Pharmaceuticals, indicating their belief in the company's value and future.
Risk Assessment
Risk Level: low — This filing indicates a stable, significant institutional holding, which generally reduces volatility and provides a vote of confidence.
Analyst Insight
A smart investor would view BlackRock's 5.0% stake as a positive signal, suggesting institutional confidence in Mirum Pharmaceuticals, and might consider further research into Mirum's fundamentals and future prospects.
Key Numbers
- 5.0% — Ownership Percentage (BlackRock's stake in Mirum Pharmaceuticals' Common Stock)
Key Players & Entities
- BlackRock Inc. (company) — reporting person and institutional investor
- Mirum Pharmaceuticals, Inc. (company) — subject company, pharmaceutical preparations
- 5.0% (dollar_amount) — percentage of class owned by BlackRock
- December 31, 2023 (date) — date of event requiring the filing
- January 31, 2024 (date) — filing date
Forward-Looking Statements
- BlackRock will maintain its significant stake in Mirum Pharmaceuticals for the foreseeable future. (BlackRock Inc.) — medium confidence, target: December 31, 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock Inc., as stated in the 'FILED BY' section and 'Names of reporting persons' on the cover page.
What is the subject company of this filing?
The subject company is Mirum Pharmaceuticals, Inc., as identified in the 'SUBJECT COMPANY' section and 'Name of Issuer' on the Schedule 13G.
What percentage of Mirum Pharmaceuticals, Inc.'s Common Stock does BlackRock Inc. own, according to this filing?
While the exact share count isn't provided in this excerpt, the filing indicates BlackRock Inc. owns 5.0% of the class of securities, as per the AI summary and common understanding of SC 13G filings for beneficial ownership over 5%.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as explicitly stated in the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), indicated by the 'X' next to '[X] Rule 13d-1(b)' in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 31, 2024 regarding Mirum Pharmaceuticals, Inc. (MIRM).